IRIDEX (IRIX) Projected to Post Quarterly Earnings on Tuesday

IRIDEX (NASDAQ:IRIX) will likely be posting its Q2 2026 results after the market closes on Tuesday, August 18th. Analysts expect the company to announce earnings of ($0.01) per share and revenue of $13.5870 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 18, 2026 at 5:00 PM ET.

IRIDEX (NASDAQ:IRIX) last announced its earnings results on Tuesday, May 19th. The medical equipment provider reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.04. The business had revenue of $11.80 million for the quarter, compared to analyst estimates of $11.91 million.

IRIDEX Stock Performance

NASDAQ:IRIX opened at $0.84 on Tuesday. IRIDEX has a one year low of $0.80 and a one year high of $1.65. The business’s 50-day simple moving average is $1.04 and its 200 day simple moving average is $1.16. The stock has a market cap of $14.66 million, a price-to-earnings ratio of -4.43 and a beta of 0.66.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $3.00.

Institutional Investors Weigh In On IRIDEX

Institutional investors have recently made changes to their positions in the company. Citadel Advisors LLC raised its position in shares of IRIDEX by 62.7% during the 3rd quarter. Citadel Advisors LLC now owns 109,473 shares of the medical equipment provider’s stock valued at $126,000 after acquiring an additional 42,202 shares in the last quarter. Susquehanna International Group LLP lifted its stake in IRIDEX by 46.2% during the third quarter. Susquehanna International Group LLP now owns 56,470 shares of the medical equipment provider’s stock worth $65,000 after purchasing an additional 17,834 shares during the last quarter. Apexium Financial LP boosted its holdings in IRIDEX by 53.0% in the third quarter. Apexium Financial LP now owns 100,529 shares of the medical equipment provider’s stock worth $116,000 after purchasing an additional 34,834 shares during the period. Finally, Jane Street Group LLC boosted its holdings in IRIDEX by 93.9% in the fourth quarter. Jane Street Group LLC now owns 31,758 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 15,377 shares during the period. 20.10% of the stock is currently owned by institutional investors.

About IRIDEX

IRIDEX Corporation (NASDAQ: IRIX) is a medical technology company specializing in the development, manufacturing and commercialization of innovative ophthalmic laser and imaging systems. The company’s offerings focus on energy-based therapies designed to treat retinal vascular disorders, glaucoma and other ocular conditions. IRIDEX’s portfolio includes laser photocoagulation platforms, micro-pulse laser technology, and related consumable devices for use by ophthalmologists and retina specialists.

The company’s flagship products include the Cyclo G6 Glaucoma Laser System, which delivers precise, controlled micro-pulse laser therapy for patients with refractory glaucoma, and the IQ 532 Retina Laser System, designed to support minimally invasive laser treatments for diabetic retinopathy and age-related macular degeneration.